Premium
Combined modality treatment of American Burkittapos;s lymphoma
Author(s) -
Ziegler John L.,
Devita Vincent T.,
Graw Robert G.,
Herzig Geoffrey,
Leventhal Brigid G.,
Levine Arthur S.,
Pomeroy Thomas C.
Publication year - 1976
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197612)38:6<2225::aid-cncr2820380606>3.0.co;2-f
Subject(s) - medicine , modality (human–computer interaction) , lymphoma , treatment modality , oncology , artificial intelligence , computer science
Fifteen American patients with Burkittapos;s lymphoma were treated in a clinical trial employing chemotherapy, radiotherapy, and immunotherapy. Two patients died during induction, and 13 achieved complete responses. Eight patients relapsed at a median of 11 weeks from initial treatment, and seven of these have died. The remaining patient has enjoyed a prolonged third remission following intensive chemotherapy and bone marrow autograft. Five patients remain in their first remission in excess of 1 year. The major therapeutic goal in the management of Burkittapos;s lymphoma is the prevention of relapse; the identification of risk factors and various strategies to achieve this goal are discussed.